Rat Hypothalamic Growth Hormone-releasing Factor Research Articles

Characterization of feeding behavior induced by central injection of GRF

The behavior resulting from injection of rat hypothalamic growth hormone-releasing factor (GRF) (0, 0.01, 0.1, 1.0 pmol) into the suprachiasmatic nucleus-medial preoptic area (SCN/MPOA) or the paraventricular nucleus (PVN) of the hypothalamus was examined. After injections of GRF, feeding and other behavioral responses of male Wistar rats were observed for 90 min. In the SCN/MPOA, GRF dose dependently increased food intake, increasing mean meal length at 0.1 pmol and increasing rate of eating with no effect on meal length at 1.0 pmol. Other behavioral measures were unaffected by GRF. There was no effect after injections into the PVN. These data are taken as confirmation that the SCN/MPOA region of the hypothalamus is important for the central stimulatory effects of GRF on feeding. The possibility that the PVN is involved in the expression of feeding derived from intra-SCN/MPOA GRF injections is discussed.

Effects of growth hormone-releasing factor and somatostatin on growth hormone secretion in hypophysial stalk-transected beef calves.

The effects of growth hormone-releasing factor (GHRF) on growth hormone (GH) secretion were studied in beef calves after hypophysial stalk transection (HST). Peripheral GH concentration during surgery was elevated for 60 min after the initiation of anesthesia to 15 ng/ml, which was greater than plasma levels after HST and during the recovery period (0-30 hr mean, 3 ng/ml; P less than 0.05). Episodic GH secretion normally seen in sham-operated controls (SOC) was abolished after HST. Before HST, calves responded to 80% of the GHRF challenges, whereas after HST calves responded to every challenge of GHRF with an increase in plasma GH. A dose of 0.067 microgram human pancreatic (hp) hpGHRF(1-40)OH/kg body wt 3 days after HST increased plasma GH to 55 ng/ml from a control period mean of 5 ng/ml (P less than 0.04). On Day 8, HST calves received two injections of 0.067 microgram hpGHRF/kg body wt at 3-hr intervals, with feeding 70 min after the first injection. During two preinjection control periods, basal GH averaged less than 4 ng/ml and increased to 17 (P less than 0.02) and 9 (P less than 0.04) ng/ml immediately after the first and second injection of hpGHRF, but the response declined over the 8-day period after surgery. On Days 19 and 20, the HST calves were infused iv with 0.033 and 0.067 microgram somatostatin(SS)-14 (SRIH)/kg body wt, during which a pulse injection of 0.067 microgram hpGHRF/kg body wt was administered. GH increased to 9 and 5 ng/ml during the 0.033- and 0.067-microgram SRIH infusions after GHRF; no somatotropic rebound was observed after the SRIH was discontinued as was seen in the animals while the hypothalamic-hypophysial connections were intact. Five and six months after HST the responses to two analogs of rat hypothalamic GHRF were similar to those in SOC calves. These results indicate that HST calves responded to exogenous GHRF with an abrupt increase in plasma GH, but GH response to GHRF during SRIH infusion was greatly inhibited.

Growth hormone-releasing factor on growth hormone secretion in prepubertal calves.

The effects of iv administration of growth hormone-releasing factor (GRF) on growth hormone (GH) release and on nitrogen metabolism were measured in prepubertal calves. Crossbred beef heifers (111 kg) were used in a Latin square design to test the effects of 0, 0.01, 0.033, 0.067, and 0.1 microgram human pancreatic (hp) GRF [hpGRF (1,40)OH]/kg body wt on plasma GH concentrations. When they were given doses of 0.067 and 0.1 microgram hpGRF/kg body wt, plasma GH increased (P less than 0.05) within 5-15 min, compared with injections of control buffer, and then returned to preinjection concentrations. The response to 0.067 microgram hpGRF/kg body wt every 3 hr for 42 hr was studied in five heifers (137 kg body wt). The animals responded to 50% of the GRF injections with an increase in plasma GH during every 6-hr period measured. Nitrogen retention, hormone concentrations, and weight gain were measured in five bull calves (90 kg body wt) administered 0 or 0.067 microgram Nle rat hypothalamic GRF (1,29)NH2/kg body wt every 4 hr for 10 days. Metabolic parameters were interpreted to indicate an anabolic response to GRF even though increases of 16% in nitrogen retention, 23% in plasma somatomedin C concentrations, and 36% in weight gain with pulsatile GRF treatment were variable and statistically similar to those of controls. These results indicate that GRF induces peak GH secretion within 15 min in prepubertal calves and that calves can respond to multiple injections of GRF with an increase in plasma GH.

Development of hypothalamic neurons in intraventricular grafts: Expression of specific transmitter phenotypes

The anlages of the medial-basal hypothalamus (MBH), septopreoptic area (POA), Rathke's pouch, and the parietal cortex (CC) of rats (at 12.5, 14.5 and 16.5 days of gestation) were transplanted singly or in combination into the third ventricle of adult female rats, and the development of neurons in the grafts was investigated immunohistochemically with the use of antisera to tyrosine hydroxylase (TH), somatostatin (SRIH), ACTH, methionine enkephalin-Arg 6-Gly 7-Leu 8 (Enk-8), rat corticotropin-releasing factor (rCRF), rat hypothalamic growth hormone-releasing factor (rhGRF), and luteinizing hormone-releasing hormone (LHRH). TH and all the peptides examined except LHRH were detected in distinct neurons in MBH grafts and in cografts of MBH plus Rathke's pouch from 12.5-day-old embryos. SRIH, rCRF, Enk-8, and TH were found in POA grafts from embryos of the same age. Although immunoreactive LHRH was first detected in neurons in POA grafts from 16.5-day-old embryos, it appeared in cografts of POA and MBH from 12.5-day-old embryos. The immunoreactive fibers developed in the grafts expressed the same characteristic behaviors as in intact brain; the fibers containing hormonal substances formed complexes with the vasculature like in the organum vasculosum laminae terminalis (OVLT) or in the median eminence, while the fibers containing neurotropic signals formed fiber networks surrounding other nerve cell bodies as if they synaptically associate. In CC grafts, the neurons contained TH, SRIH, rCRF, or Enk-8, and their axonal processes formed fiber networks. These findings suggest that all the hypothalamic neurons examined are committed by 12.5 days of gestation to develop maintaining transmitter phenotype and target recognition capacity.

Centrally administered hypothalamic growth hormone-releasing factor stimulates food intake in free-feeding rats.

Intracerebroventricular injections of rat hypothalamic growth hormone-releasing factor (rhGRF) were examined for effects on food intake in free-feeding rats. It was found that, in picomole doses, rhGRF had a stimulatory effect on food intake. Examination of higher doses of rhGRF revealed a decrease in the facilitatory effects and an inhibitory trend at the highest dose (4 nanomoles). The present results are consistent with previous results from our laboratory showing that central injections of rhGRF stimulate food intake in food-deprived rats.

Ultrastructural evidence for neuronal regulation of growth hormone secretion.

The morphological substrate for the central mechanisms that control growth hormone (GH) release in the rat hypothalamus was investigated immunohistochemically by light and electron microscopy. In electron-microscopic studies, a dual immunolabeling technique was employed to demonstrate pairs of peptides, i.e. rat hypothalamic growth hormone-releasing factor (rhGRF) and somatostatin (SRIH), rhGRF and substance P (SP), and rhGRF and methionine-enkephalin-Arg6-Gly7-Leu8 (Enk-8), in different neuronal structures. Immunoreactivity of rhGRF was detected as silver-gold particles and those of the other substances as diaminobenzidine products by preembedding immunostaining procedures. In the external layer of the median eminence, axonal terminals immunolabeled for rhGRF and for SRIH showed the same pattern of distribution and close proximity. The neuronal inputs to GRF cell bodies in the arcuate nucleus were examined, and SRIH, SP and Enk-8 fibers with varicosities were found to form dense networks around the perikarya of GRF neurons, suggesting the presence of synaptic associations. Axonal terminals immunolabeled for SRIH, SP or Enk-8, and unlabeled terminals appeared to form coincidental synaptic junctions on GRF perikarya. These findings suggest that the central regulation of GH release occurs at the levels of the median eminence and the cell bodies.

Naloxone blockade of growth hormone-releasing factor-induced feeding.

The opiate antagonist naloxone was used to examine the possibility that endogenous opioid function is involved in the expression of the increased feeding observed following intracerebroventricular (i.c.v.) administration of rat hypothalamic growth hormone-releasing factor (GRF). It was found that systemically administered naloxone (0.125, 0.25 and 0.50 mg/kg) significantly suppressed the increased food intake observed following i.c.v. GRF (4.0 pmol) treatment. Though potent enough to eliminate ingestive effects of GRF, baseline food intake was unaffected by 0.125 mg/kg naloxone. Examination of 0.4, 4.0 and 40.0 pmol i.c.v. administered GRF-(3-40), a structurally related but physiologically inactive peptide, revealed no effect on food intake. The present results suggest involvement of endogenous opioid function in GRF-stimulated feeding.

Growth hormone secretion from chicken adenohypophyseal cells in primary culture: Effects of human pancreatic growth hormone-releasing factor, thyrotropin-releasing hormone, and somatostatin on growth hormone release

A primary culture of chicken adenohypophyseal cells has been developed to study the regulation of growth hormone (GH) secretion. Following collagenase dispersion, cells were exposed for 2 hr to vehicle (control) or test agents. Human pancreatic (tumor) growth hormone-releasing factor (hpGRF) and rat hypothalamic growth hormone-releasing factor stimulated GH release to similar levels. GH release was increased by the presence of dibutyryl cyclic AMP. Thyrotropin-releasing hormone (TRH) alone did not influence GH release; however, TRH plus hpGRF together exerted a synergistic (greater than additive) effect, increasing GH release by 100 to 300% over the sum of the values for each secretagogue acting alone. These relationships between TRH and hpGRF were further examined in cultured cells exposed to secretagogues for two consecutive 2-hr incubations. TRH pretreatment enhanced subsequent hpGRF-stimulated GH release by about 80% over that obtained if no secretagogue was present during the first incubation. In other experiments, somatostatin (SRIF) alone did not alter GH secretion. However, SRIF reduced hpGRF-stimulated GH release to levels found in controls. Furthermore, GH release stimulated by the presence of both TRH and hpGRF was lowered to control values by SRIF. The results of these studies demonstrate that a primary culture of chicken adenohypophyseal cells is a useful model for the study of GH secretion. Indeed, these results suggest that TRH and hpGRF regulate GH secretion by mechanisms which are not identical.

Influence of Coexisting Hypothalamic Messengers on Growth Hormone Secretion from Rat Anterior Pituitary Cells in vitro

An increasing number of messengers have recently been found to coexist with growth hormone (GH)-releasing factor (GRF) in hypothalamic neurons. In view of a possible cosecretion of these substances with GRF into the portal circulation, the effect of synthetic rat hypothalamic GRF(1-43) alone, or together with dopamine (DA), L-dopa, gamma-aminobutyric acid (GABA), neurotensin (NT) or galanin (GAL) on GH release was investigated by using dispersed rat anterior pituitary cells in monolayer culture. GRF in concentrations of 10(-16)-10(-7) M stimulated GH release from somatotrophs in a dose-related manner. DA (10(-5) M), L-dopa (10(-8) and 10(-5) M) and GABA (10(-9) and 10(-5) M) did not affect basal GH release, whereas DA, but not L-dopa or GABA, significantly suppressed GRF-induced GH secretion. However, the inhibitory effect of DA on GRF-stimulated GH secretion was not observed in the presence of somatostatin (10(-6) M). NT (10(-6) M) and GAL (10(-6) M) did not change basal GH release. GAL, but not NT, inhibited GRF-stimulated GH release, but the addition of NT abolished the inhibitory actions of both GAL and DA. These results indicate that substances, probably coreleased with GRF from the same nerve endings, interact in the regulation of GH secretion at the pituitary level.

Immunohistochemical localization of GRF-containing neurons in rat brain.

Brains from 4 normal and 4 colchicine-treated rats were studied for the presence of growth hormone-releasing factor (GRF) using an antibody directed against rat hypothalamic GRF (rGRF). Noncolchicine-treated animals showed intense staining in the external layer of the median eminence. Rats pretreated with intraventricular colchicine for 48 h showed localization of GRF-containing cell bodies in the arcuate nucleus, the perifornical area, the lateral basal hypothalamic region and lateral to the ventromedial nucleus and the premammillary nucleus. This pattern of distribution is consistent with the postulated role of GRF in hypothalamic regulation of growth hormone secretion. Our results confirm the predominant localization of GRF perikarya in the arcuate nucleus of the rat which has been noted in studies using antibodies directed against both human pancreas GRF (hpGRF) and rGRF, and demonstrate a unique pattern of rGRF-positive cell bodies elsewhere in the hypothalamus. No rGRF perikarya or processes were seen outside the hypothalamus.

The distribution of growth-hormone-releasing factor (GRF) immunoreactivity in the central nervous system of the rat: an immunohistochemical study using antisera directed against rat hypothalamic GRF.

Immunohistochemical methods have been used to chart the distribution of rat hypothalamic growth-hormone-releasing factor (rhGRF) immunoreactivity in the brains of normal and colchicine-treated adult albino rats. The results suggest the existence of at least two distinct rhGRF-containing systems: one responsible for delivery of the peptide to portal vessels in the median eminence, and one whose relationship, if any, to hypophysiotropic function is less direct. A dense plexus of rhGRF-stained fibers was found throughout the external lamina of the median eminence that is the route by which the peptide is delivered to the anterior pituitary. This projection appears to arise primarily from a group of rhGRF-immunoreactive neurons centered in the arcuate nucleus. Some 1,000-1,500 rhGRF-positive neurons were counted on each side of the brain in rats pretreated with colchicine. Colocalization studies, using a sequential double staining technique, indicated that a subset of rhGRF-immunoreactive neurons in the arcuate region contain neurotensin immunoreactivity. No evidence was obtained for colocalization of rhGRF with either of two pro-opiomelanocortin-derived peptides (alpha-melanocyte-stimulating hormone, adrenocorticotropic hormone (1-24)) in individual neurons in the arcuate nucleus. Much smaller groups of neurons were localized in the parvicellular division of the paraventricular nucleus of the hypothalamus and in the dorsomedial nucleus, and it is unclear whether they contribute to the plexus of rhGRF-stained fibers in the median eminence. The only other region in the rat brain in which rhGRF-stained cells were found reliably was in the area that roughly encapsulates the caudal aspect of the ventromedial nucleus of the hypothalamus. Because cells in this region are not known to project to the median eminence, they may be assumed to contribute to the extrahypophysiotropic rhGRF-stained projections outlined below. From the level of the arcuate and ventromedial nuclei, rhGRF-immunoreactive fibers could be traced along the base of the brain and through the periventricular system to discrete terminal fields limited almost exclusively to the hypothalamus and adjoining parts of the basal telencephalon. All parts of the periventricular region of the hypothalamus receive an input, including the preoptic and anterior parts in which somatostatin-containing neurons that project to the median eminence are clustered. Other prominent terminal fields were localized in discrete parts of the dorsomedial, paraventricular, suprachiasmatic, and premammillary nuclei, and in the medial preoptic and lateral hypothalamic areas.(ABSTRACT TRUNCATED AT 400 WORDS)

Levels of human and rat hypothalamic growth hormone-releasing factor as determined by specific radioimmunoassay systems.

Polyclonal antibodies to synthetic human pancreatic growth hormone-releasing factor [hpGRF(1-44)NH2] and rat hypothalamic growth hormone-releasing factor [rhGRF(1-43)OH] were produced in rabbits by injecting these weak immunogens, coupled to thyroglobulin and emulsified with complete Freund's adjuvant in the presence of activated charcoal, directly into the spleen. A subsequent booster injection by the conventional intramuscular route resulted in high-titer antibodies, which at a 1:20,000 dilution were used to develop highly sensitive and specific radioimmunoassays for these peptides. By using antibodies with an apparent Ka of 3.3 X 10(-12) (human) and 7.7 X 10(-11) (rat), the sensitivity of these assays in both human and rat was found to be less than 1 fmol. The antibody to hpGRF(1-44)NH2 is directed against the COOH-terminal region of the molecule, as shown by its crossreactivity with various hpGRF analogues: 140% with hpGRF(30-44)NH2; 1%-2% with hpGRF(1-37)OH, hpGRF(1-40)OH, and hpGRF(1-40)NH2; and none with hpGRF(1-29)NH2. Serial dilutions of human and rat hypothalamic extracts demonstrated parallelism with the corresponding species-specific standard and 125I-labeled tracer. There was no crossreactivity with other neuropeptides, gastrointestinal peptides, or hypothalamic extracts of other species. The hypothalamic content in fmol/mg (wet weight) of tissue was 3.6 +/- 0.2 for the human and 11.1 +/- 5.5 for the rat. Age-related changes in hypothalamic GRF content were present in rats, with a gradual increase from 2 to 16 weeks and a correlation between increasing body weight and GRF content. These radioimmunoassays will serve as important tools for understanding the regulation of growth hormone secretion in both human and rat.

Characterization of cDNA and genomic clones encoding the precursor to rat hypothalamic growth hormone-releasing factor.

Growth hormone-releasing factor (GHRF) is a hypothalamic peptide which positively regulates the synthesis and secretion of growth hormone in the anterior pituitary. The amino-acid sequence of a 43-residue GHRF peptide isolated from rat hypothalamus was recently determined. Immunocytochemical techniques have been used to localize GHRF-containing cell bodies and nerve fibres largely to the medial-basal region of the rat hypothalamus. The rat has also been used extensively as an animal model to study the effects of GHRF on growth hormone synthesis and secretion and on somatic growth. To pursue questions concerning the biosynthesis of GHRF, the expression of the ghrf gene, and its regulation in the hypothalamus by neural and hormonal influences, we have now isolated and characterized both complementary DNA and genomic clones encoding rat hypothalamic GHRF. The rat ghrf gene spans nearly 10 kilobases (kb) of rat genomic DNA, contains 5 exons and encodes a 104-amino-acid precursor to the rat GHRF peptide. Comparison with previously characterized human ghrf cDNA and genomic clones has allowed patterns of conservation of amino-acid and nucleotide sequences between the human and rat GHRFs to be determined.

Effect of different growth hormone-releasing factors on the concentrations of growth hormone, insulin and metabolites in the plasma of sheep maintained in positive and negative energy balance

Three experiments were conducted to compare the ability of different preparations of growth hormone-releasing factor (GRF) to stimulate GH secretion in sheep maintained in positive and negative energy balance. In experiment 1 five sheep were injected (i.v.) with three preparations of human pancreatic GRF (hpGRF-44, hpGRF-40, hpGRF-29-NH2) and one preparation of rat hypothalamic GRF (rhGRF-29-NH2) all at 98.0 pmol/kg, or control vehicle, in a Latin square design when the animals either had free access to food or were fed half their maintenance requirements. Analysis of plasma samples, obtained before and for 150 min after injection, revealed that the reduced food intake resulted in the expected changes in body weight and circulating GH, insulin, glucose, urea and non-esterified fatty acids. The maximum post-injection concentrations of GH did not differ between either the two levels of feeding or the four GRF preparations but the mean post-injection concentration of GH was significantly higher for all GRF treatments on the restricted ration (P less than 0.001). The mean post-injection response to rhGRF-29-NH2 was less than that obtained with hpGRF-44 for sheep with food available ad libitum (P less than 0.05) and was clearly more persistent for all GRF treatments in animals fed the reduced diet (P less than 0.001). In experiment 2 the same five sheep were injected i.v. with rhGRF-29-NH2 (98.0 pmol/kg) when they had free access to food and after food had been withdrawn for 3 days.(ABSTRACT TRUNCATED AT 250 WORDS)

Rat hypothalamic growth hormone-releasing factor: Isolation, sequence analysis and total synthesis

Growth hormone-releasing factor (GRF) was isolated from acid extracts of approximately 35,000 rat hypothalami by means of immunoaffinity chromatography, gel filtration and two steps of reverse-phase HPLC. Amino acid analysis, gas-liquid phases sequencing and peptide mapping established that rat GRF is a 43 amino acid peptide with the amino acid sequence His-Ala- Asp-Ala-Ile-Phe-Thr-Ser-Ser-Tyr-Arg-Arg-Ile-Leu-Gly-Gln-Leu-Tyr-Ala-Arg-Lys- Leu-Leu-His-Glu-Ile-Met-Asn-Arg-Gln-Gln-Gly-Glu-Arg-Asn-Gln-Glu-Gln-Arg-Ser- Arg-Phe-Asn-OH, confirming the primary structure reported earlier (Spiess et al Nature 303 , 532 (1983).

Evidence that opiatergic and alpha-adrenergic mechanisms stimulate rat growth hormone release via growth hormone-releasing factor (GRF).

An antiserum raised against human pancreatic growth hormone-releasing factor-(1-40) (hpGRF-40) was found to recognize the rat hypothalamic growth hormone-releasing factor (rhGRF): This antiserum, when given iv to adult male rats, completely abolished GH release induced by a synthetic rhGRF (0.2, 1 microgram/kg BW), and inhibited the physiological GH secretion over 2 days. After passive immunization with anti-hpGRF-40 serum, iv injection of either FK 33-824 (100 micrograms/kg BW), an enkephalin analogue, or clonidine (125 micrograms/kg BW), an alpha-adrenergic agent, failed to stimulate GH release in the unanesthetized rat. These results indicate that the GH-releasing actions of opiatergic and alpha-adrenergic mechanisms are mediated through stimulation of endogenous rhGRF release in the rat.

Specific depletion of immunoreactive growth hormone-releasing factor by monosodium glutamate in rat median eminence.

A potent and specific growth hormone-releasing factor (GRF) was recently isolated and characterized from a human islet cell tumour of the pancreas that caused acromegaly. Antibodies raised against the synthetic replicate of this peptide have allowed the immunohistochemical identification of GRF-producing neurones within the primate central nervous system. Such neurones are found mainly in the arcuate nucleus in human and monkey hypothalamus, suggesting that this nucleus is a primary source of GRF. We have further investigated this hypothesis by studying the anatomical organization of GRF neurones in rat hypothalamus, using an antibody raised against the recently characterized rat hypothalamic GRF in normal animals and in animals neonatally treated with monosodium glutamate (MSG), a treatment which results in the selective destruction of arcuate nucleus neurones. We present here the results which show that GRF-producing neurones are located mainly in the arcuate nucleus of rats. MSG treatment results in the complete loss of GRF-immunoreactive cell bodies within this nucleus and provokes a selective disappearance of GRF-immunoreactive fibres in the median eminence. These results show that the arcuate nucleus is the origin of the GRF-containing fibres that project to the median eminence and establish the MSG-treated rat as an in vivo model for studying growth hormone secretion in the absence of neurohumoral GRF.

Invivo biological potency of rat and human growth hormone-releasing factor and fragments of human growth hormone-releasing factor

The biological potency of the synthetic replicates of three peptides isolated from a human pancreatic tumor with growth hormone releasing activity and rat hypothalamic growth hormone-releasing factor was evaluated in conscious freely-moving rats and anesthetized rats. All 4 peptides are equipotent on a molar basis in their ability to stimulate GH secretion. Studies with synthetic fragments of the human derived material indicated that the amino-terminal amino acid is required for activity. Deletion of as many as 13 amino acids from the carboxy-terminal failed to decrease GH-releasing activity; however, deletion of 16 amino acids resulted in a significant decrease and deletion of 20 amino acids resulted in complete loss of bioactivity.

A noninvasive functional lesion of the hypothalamo-pituitary axis for the study of growth hormone-releasing factor.

Rats were passively immunized with an antiserum against somatostatin and a monoclonal antibody against rat hypothalamic growth hormone-releasing factor (rGRF-mAb) which does not recognize the biologically active 1-40 amino acid fragment of hpGRF-44 (hpGRF-40). Using this paradigm we have observed that the pituitary possesses a resilient capacity to release growth hormone (GH) following repeated injections of hpGRF-40 and that this response follows a dose-dependent relationship.

Monoclonal antibodies to hypothalamic growth hormone-releasing factor with picomoles of antigen.

Monoclonal antibodies specific for rat hypothalamic growth hormone-releasing factor (rGRF) have been produced by in vitro immunization of mouse spleen cells with less than 1 nanomole of rGRF in a partially purified preparation. Hybridoma supernatants were screened for anti-rGRF activity by use of a pituitary culture assay system that can detect growth hormone-releasing factor in the femtomole range. Such highly sensitive in vitro techniques permit the use of picomole quantities of an antigen in partially purified preparations for the isolation of monoclonal antibodies, which can in turn be used in biological studies and in immunochemical procedures for large-scale purification and isolation of that antigen.